Gratus Capital LLC Biogen Inc. Transaction History

Gratus Capital LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 27, 2023	SELL	$252.44 - $306.72 $32,817 - $39,873	-130 Reduced 12.56%	905 $0
Q1 2022 Apr 29, 2022	SELL	$193.77 - $244.14 $387 - $488	-2 Reduced 0.19%	1,035 $218,000
Q4 2021 Jan 31, 2022	BUY	$223.92 - $287.77 $447 - $575	2 Added 0.19%	1,037 $249,000
Q3 2021 Nov 05, 2021	BUY	$282.99 - $369.05 $48,957 - $63,845	173 Added 20.07%	1,035 $293,000
Q2 2021 Aug 10, 2021	SELL	$259.0 - $414.71 $48,692 - $77,965	-188 Reduced 17.9%	862 $298,000
Q2 2020 Aug 11, 2020	SELL	$258.66 - $342.55 $15,778 - $20,895	-61 Reduced 5.49%	1,050 $281,000
Q1 2020 May 01, 2020	BUY	$268.85 - $341.04 $16,399 - $20,803	61 Added 5.81%	1,111 $351,000
Q1 2019 May 14, 2019	SELL	$216.71 - $338.96 $54,177 - $84,740	-250 Reduced 19.23%	1,050 $248,000
Q4 2018 Feb 14, 2019	SELL	$278.5 - $352.75 $83,550 - $105,825	-300 Reduced 18.75%	1,300 $391,000
Q4 2018 Feb 13, 2019	BUY	$278.5 - $352.75 $153,175 - $194,012	550 Added 52.38%	1,600 $481,000
Q1 2018 May 10, 2018	BUY	$260.13 - $367.91 $33,816 - $47,828	130 Added 14.13%	1,050 $288,000
Q2 2017 Aug 08, 2017	BUY	N/A	920	920 $250,000

1,032

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Gratus Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Gratus Capital LLC with notifications on news.